Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai 18-09-2024, 22:07

Notification under Chapter 9, Section 10 of the Finnish 1-03-2023, 13:32

Origin Enters into Binding Letter of Intent with Safe 1-02-2023, 03:37